Q-omics provides the consensus-scored CCR12P profile across patient tissues and cancer cell-line models. CCR12P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CCR12P is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, CCR12P RNA expression shows 9,716 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, COAD, and THYM as cancer lineages where CCR12P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCR12P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCR12P survival associations across molecular data types. CCR12P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCR12P RNA expression–survival associations across cancer types. High CCR12P expression shows unfavorable associations in COAD, ACC, THCA, LUAD and DLBC, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for CCR12P RNA expression.
This table summarizes CCR12P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CCR12P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCR12P shows lower tumor expression in COAD and THCA. The COAD box plot shows higher CCR12P RNA expression in normal versus tumor tissue (log2 FC = −0.100, t-test p < 0.001).
This table shows molecular features associated with CCR12P in patient tissues and cancer cell lines. In patient samples, CCR12P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
